Companies: 10,795·Total market cap: $144.5T
Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc.

RLMDNASDAQHealthcare● Active
$5.72
$-0.23(-3.87%)
Market Cap$419468318
P/E Ratio
52W High$8
52W Low$0.52
Overview

Relmada Therapeutics, Inc. (RLMD) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · RLMD · as of Jun 9, 2026

Key Statistics

EPS (TTM)$-1.11rlmd eps ttm · rlmd earnings per shareEarnings history
PE Ratio (TTM)rlmd pe ratio ttm · rlmd price to earningsPE Ratio deep dive
Revenue (TTM)0.00rlmd revenue ttm · rlmd annual revenueFull revenue history
Dividend YieldNo Dividenddoes rlmd pay dividends · rlmd dividend yieldDividend history
Shares Outstanding39.5Mrlmd shares outstanding · rlmd floatShares outstanding history
Next EarningsAug 6, 2026Est.rlmd earnings date · rlmd next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$0.00
202320242025
relmada therapeutics, inc. revenue · rlmd revenue 2025
FY 2025Net Income-$57.4M▲ +28.25% YoY
202320242025
relmada therapeutics, inc. net income · rlmd profit 2025
FY 2025EPS$-1.45▲ +45.28% YoY
202320242025
rlmd eps · relmada therapeutics, inc. earnings per share 2025
TTM:Revenue: $0.00Net Income: -$58.9MEPS: $-1.11View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy8 analystsis rlmd a buy · rlmd analyst rating
Strong Buy
0
Buy
5
Hold
2
Sell
1
Strong Sell
0
12-Month Price Target
$8.00Low
$5.72Current
$9.00Avg Target57.34% upside
$10.00High
rlmd price target · rlmd 12 month forecast

Total: 8 · Buy rate: 62.5%

The RLMD analyst consensus is Buy, based on ratings from 8 Wall Street analysts over the past 3 months. The average 12-month price target is $9.00, representing +57.34% upside from the current price of $5.72.

Stock Performance

Full History
1D-3.87%
1W-9.35%
1M-21.86%
3M-20.22%
YTD+18.43%
1Y+592.08%
5Y-6.54%

About Relmada Therapeutics, Inc.

CEOSergio Traversa
IPO DateJun 20, 2014
Employees17
CountryUS

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology firm, concentrating its efforts on developing various therapeutic solutions for ailments affecting the central nervous system (CNS…

what is relmada therapeutics, inc. · rlmd stock overview · relmada therapeutics, inc. company profile · who is relmada therapeutics, inc. ceo · rlmd NASDAQ · relmada therapeutics, inc. headquarters · relmada therapeutics, inc. business segments

About Stock Overview & Key Data

Relmada Therapeutics, Inc. (RLMD) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jun 20, 2014. As of the latest trading session, RLMD stock price is $5.72, with a market capitalization of $419.5M. The stock has returned +592.08% over the past 12 months and +18.43% year-to-date.

According to 8 Wall Street analysts, the consensus rating for Relmada Therapeutics, Inc. stock is Buy, with an average 12-month price target of $9.00. In fiscal year 2025, Relmada Therapeutics, Inc. reported revenue of — and net income of -$57.4M. For detailed data — including Relmada Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Relmada Therapeutics, Inc. (RLMD) stock price is $5.72. The stock is traded on NASDAQ under the ticker symbol RLMD. The 52-week range is $0.52 – $8.00.

RLMD stock priceRLMD quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice